What's in Celgene's pipeline?

Celgene has 56 drugs in our index: 3 marketed, 0 filed, 15 in Phase 3, 17 in Phase 2, 20 in Phase 1.

Which companies overlap with Celgene's portfolio?

Top competitors by shared drug class: Hoffmann-La Roche, Merck Sharp & Dohme LLC, Sun Yat-sen University, Kite, A Gilead Company, Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/celgene.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Celgene — Portfolio Competitive Intelligence Brief

Celgene pipeline: 3 marketed, 0 filed, 15 Phase 3, 17 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 15 Phase 3 17 Phase 2 20 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
low-dose dexamethasone	low-dose dexamethasone	marketed	Corticosteroid	Glucocorticoid receptor	Immunology
Pneumococcal polysaccharide vaccine	Pneumococcal polysaccharide vaccine	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)	Immunology / Infectious Disease
Istodax	Istodax	marketed		Bromodomain-containing protein 4, Histone deacetylase 3/NCoR1, Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2)	Oncology
Placebo to ozanimod	Placebo to ozanimod	phase 3	Sphingosine-1-phosphate (S1P) receptor modulator	S1P1 and S1P5 receptors	Immunology
Conventional Care Regimen	Conventional Care Regimen	phase 3
Abraxane (Maintenance)	Abraxane (Maintenance)	phase 3	Microtubule stabilizer (taxane)	Beta-tubulin / microtubules	Oncology
Lenalidomide and low-dose dexamethasone	Lenalidomide and low-dose dexamethasone	phase 3	Immunomodulatory agent + corticosteroid	Cereblon (CRBN), TNF-α pathway; glucocorticoid receptor	Oncology
CC-93538	CC-93538	phase 3	Cereblon E3 ligase modulator (CELMoD)	Cereblon (CRBN); Ikaros (IKZF1); Ikzf3	Oncology
BMS-986365	BMS-986365	phase 3	Menin inhibitor	Menin (MEN1)	Oncology
CC-5013 plus dexamethasone	CC-5013 plus dexamethasone	phase 3	Immunomodulatory agent plus corticosteroid	Cereblon (CRBN); glucocorticoid receptor	Oncology
Abraxane (Induction)	Abraxane (Induction)	phase 3	Microtubule stabilizer (taxane)	β-tubulin / microtubules	Oncology
Carboplatin (Induction)	Carboplatin (Induction)	phase 3	Platinum-based chemotherapy agent	DNA	Oncology

Therapeutic area mix

Oncology · 17
Immunology · 4
Other · 4
Hematology/Oncology · 1
Immunology / Infectious Disease · 1
Immunology, Rheumatology, Oncology (supportive care), Endocrinology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hoffmann-La Roche · 5 shared drug classes
Merck Sharp & Dohme LLC · 5 shared drug classes
Sun Yat-sen University · 3 shared drug classes
Kite, A Gilead Company · 3 shared drug classes
Pfizer · 3 shared drug classes
Sanofi · 3 shared drug classes
Assistance Publique - Hôpitaux de Paris · 3 shared drug classes
Teva Branded Pharmaceutical Products R&D, Inc. · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Celgene:

Cite this brief

Drug Landscape (2026). Celgene — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/celgene. Accessed 2026-05-13.